The present invention relates to pharmaceutical compositions that include
a targeting peptide, a protease specific cleavable peptide, and a
chemotherapeutic drug that when conjugated are substantially inactive,
but upon degradation of the cleavable sequence by a proteolytic enzyme
abundant in or within the target cancer cell, the chemotherapeutic drug
is released and becomes active, and to methods of use of these
compositions for treatment of cancer.